Huang Alexander A, Huang Samuel Y
Department of Statistics and Data Science Cornell University Ithaca New York USA.
Northwestern University Feinberg School of Medicine Chicago Illinois USA.
Health Sci Rep. 2023 Apr 18;6(4):e1222. doi: 10.1002/hsr2.1222. eCollection 2023 Apr.
Diabetes mellitus is a chronic health condition that has been linked with an increased risk of severe illness and mortality from COVID-19. In Mexico, the impact of diabetes on COVID-19 outcomes in hospitalized patients has not been fully quantified. Understanding the increased risk posed by diabetes in this patient population can help healthcare providers better allocate resources and improve patient outcomes.
The objective of this study was to quantify the extent outcomes (pneumonia, intensive care unit [ICU] stay, intubation, and death) are worsened in diabetic patients with COVID-19.
Between April 14, 2020 and December 20, 2020 (last accessed), data from the open-source COVID-19 database maintained by the Mexican Federal Government were examined. Utilizing hospitalized COVID-19 patients with complete outcome data, a retrospective cohort study ( = 402,388) was carried out. In relation to COVID-19, both univariate and multivariate logistic regression were used to investigate the effect of diabetes on specific outcomes.
The analysis included 402,388 adults (age >18) with confirmed hospitalized COVID-19 cases with mean age 46.16 (standard deviation = 15.55), 214,161 (53%) male. The outcomes delineated included pneumonia ( = 88,064; 22%), ICU requirement ( = 23,670; 6%), intubation ( = 23,670; 6%), and death ( = 55,356; 14%). After controlling for confounding variables diabetes continued to be an independent risk factor for both pneumonia (odds ratio [OR]: 1.8, confidence interval [CI]: 1.76-1.84, < 0.01), ICU requirement (OR: 1.09, CI: 1.04-1.14, < 0.01), intubation (OR: 1.07, CI: 1.04-1.11, < 0.01), and death (OR: 1.88, CI: 1.84-1.93, < 0.01) in COVID-19 patients.
According to the study, all outcomes (pneumonia, ICU requirement, intubation, and death) were greater among hospitalized individuals with diabetes and COVID-19. Additional study is required to acquire a better understanding of how diabetes affects COVID-19 outcomes and to develop practical mitigation techniques for the risk of severe sickness and complications in this particular patient population.
糖尿病是一种慢性健康状况，与感染新型冠状病毒肺炎（COVID-19）后罹患重症及死亡风险增加有关。在墨西哥，糖尿病对住院患者COVID-19治疗结果的影响尚未得到充分量化。了解糖尿病在该患者群体中带来的风险增加，有助于医疗服务提供者更好地分配资源并改善患者治疗结果。
本研究的目的是量化COVID-19糖尿病患者的病情恶化程度（肺炎、入住重症监护病房[ICU]、插管和死亡）。
在2020年4月14日至2020年12月20日（最后访问时间）期间，对墨西哥联邦政府维护的开源COVID-19数据库中的数据进行了检查。利用具有完整治疗结果数据的COVID-19住院患者，开展了一项回顾性队列研究（n = 402,388）。针对COVID-19，采用单变量和多变量逻辑回归来研究糖尿病对特定治疗结果的影响。
分析纳入了402,388例确诊为COVID-19的住院成年患者（年龄>18岁），平均年龄46.16岁（标准差 = 15.55），男性214,161例（53%）。所描述的治疗结果包括肺炎（n = 88,064；22%）、需要入住ICU（n = 23,670；6%）、插管（n = 23,670；6%）和死亡（n = 55,356；14%）。在控制混杂变量后，糖尿病仍然是COVID-19患者发生肺炎（比值比[OR]：1.8，置信区间[CI]：1.76 - 1.84，P < 0.01）、需要入住ICU（OR：1.09，CI：1.04 - 1.14，P < 0.01）、插管（OR：1.07，CI：1.
